Medical Ethics & Patient AutonomyPresentation

Human dignity is the idea that every person has inherent worth — regardless of their health status, cognitive ability, age, or social standing. In health care, it’s not abstract: it shows up in how you speak to a patient, whether you explain procedures before performing them, and whether you treat someone differently because they’re elderly or incarcerated or unable to communicate. Your presentation should connect dignity to the Nuremberg atrocities — what happened was a catastrophic denial of human dignity at the most clinical level.

Autonomy is the patient’s right to make decisions about their own body and treatment — including the right to refuse care. It’s the principle that grounds informed consent. In clinical practice, autonomy can be complicated: a patient with dementia, a minor, or someone in psychiatric crisis may have limited capacity to exercise autonomous choice. Your presentation should flag that complexity — it sets up the Belmont discussion of special populations nicely. Approach these two concepts together on a single slide, using the Belmont Report’s “respect for persons” principle as the scholarly framework linking them.

Patient advocacy is the health care professional’s active role in protecting the patient’s interests — sometimes from institutional pressures, sometimes from the patient’s own family, and occasionally from other members of the care team. It’s not passive. A health care professional who advocates effectively speaks up, documents concerns, escalates when necessary, and centers the patient’s expressed wishes over others’ convenience.

Professional responsibility encompasses the obligations a health care provider assumes by virtue of their training and licensure — honesty with patients, competent practice within scope, maintaining confidentiality, and reporting concerns about unsafe or unethical conduct. It’s the bridge between personal ethics and institutional accountability. For your presentation, this connects to competency 3.1 — ethical standards as they relate to scope of practice and regulatory compliance.

Informed consent gets its own space. It’s not a signature on a form. Informed consent requires three elements: disclosure (the patient receives sufficient information about the procedure, risks, benefits, and alternatives), comprehension (the information is provided in a way the patient can understand), and voluntariness (the decision is made freely, without coercion). All three elements appear in the Belmont Report’s discussion of respect for persons, and the absence of genuine informed consent was central to the Nuremberg trials. That historical thread ties your slide directly to the next section of the presentation.

During World War II, Nazi physicians conducted systematic medical experiments on concentration camp prisoners — including hypothermia experiments, high-altitude experiments, infectious disease exposure, and forced surgery — without consent, without therapeutic intent, and without any regard for survival. The Nuremberg Doctors’ Trial (1946–1947) prosecuted 23 defendants, resulting in seven executions. The tribunal’s judgment produced the Nuremberg Code: ten principles for the ethical conduct of human experimentation.

The most important principle: voluntary consent is “absolutely essential.” No subject can be coerced, manipulated, or uninformed. The experiment must be designed to produce socially useful results. The risk to the subject must never exceed the importance of the problem being studied. And the subject must be free to withdraw at any time. These weren’t novel ideas — they were articulations of what should have been obvious. The Code’s contribution was making them legally and morally binding in an international context.

For your presentation slide, frame the Nuremberg Code as the first internationally recognized ethical standard for human subjects research — not as a historical curiosity, but as the foundation on which every subsequent framework was built. The article “The Nuremberg Code 70 Years Later” from your topic resources puts it directly: the Code remains a touchstone for research ethics globally, even as later documents have built upon it.

The Declaration of Helsinki was adopted by the World Medical Association in 1964 and has been revised seven times, most recently in 2013. It addressed a gap the Nuremberg Code left open: the Code focused on experimental research; Helsinki extended ethical requirements to therapeutic research involving patients — where a physician might simultaneously be treating a patient and conducting research on them. That dual-role situation creates obvious conflicts of interest, and Helsinki established that the patient’s welfare always takes precedence over research objectives.

Helsinki also introduced the concept of independent ethics committee review — the institutional precursor to what became IRBs in the United States. Key additions across its revisions include requirements for study protocols to be reviewed before initiation, requirements for post-trial access to beneficial treatments for participants, and protections for research in developing countries where regulatory oversight may be weaker. Your presentation should show Helsinki as an evolving document, not a static one — its revision history reflects how research ethics has matured in response to new challenges.

The Nuremberg Code and Declaration of Helsinki were international frameworks. The United States developed its own institutional mechanism — IRBs — largely in response to domestic research scandals. The most significant was the Tuskegee Syphilis Study, in which the U.S. Public Health Service tracked 399 Black men with syphilis from 1932 to 1972 without telling them their diagnosis, withholding treatment even after penicillin became the standard of care, and continuing the study after its ethical problems were repeatedly flagged internally.

When the Tuskegee study became public in 1972, the resulting congressional response was the National Research Act of 1974, which created the National Commission for the Protection of Human Subjects — the body that produced the Belmont Report in 1979. The Act also mandated IRB review for federally funded human subjects research. IRBs are institutional committees that independently review research protocols before they begin, assessing risk-benefit ratios, informed consent procedures, and protections for vulnerable populations. They are now required by federal regulation (45 CFR 46, the “Common Rule”) for virtually all federally funded research involving human subjects. Your slide on IRBs should position them as the institutional implementation of the principles established by the Nuremberg Code and Belmont Report — the mechanism that turns ethical principles into enforceable review.

Children cannot give legally valid informed consent. Belmont’s principle of “respect for persons” addresses this directly: individuals who are not capable of self-determination (including children) are entitled to protection and require a proxy decision-maker. In research involving minors, parents or legal guardians must provide permission, and children themselves must provide assent — meaning their willingness to participate should be sought in an age-appropriate manner, even if they can’t legally consent.

Your slide should explain that this protection exists because children are more vulnerable to persuasion by authority figures, cannot fully understand risk disclosures, and may be subject to parental pressures. Additional federal protections for children in federally funded research (Subpart D of 45 CFR 46) require IRBs to evaluate whether the research presents greater than minimal risk and whether any anticipated benefit justifies that risk — a higher bar than for adult subjects.

Prisoners present a specific type of vulnerability: their circumstances compromise the voluntariness of consent. When your freedom depends on cooperation with institutional authorities, participation in a research study may not feel genuinely voluntary — even if researchers intend it to be. The Belmont Report identifies this structural coercion as a reason for heightened protections. Subpart C of 45 CFR 46 specifically restricts the types of research that can be conducted on prisoners to studies directly related to incarceration itself or to conditions that disproportionately affect incarcerated populations.

For your presentation, frame this example around the concept of voluntariness within Belmont’s informed consent requirements. The protection isn’t that prisoners can never participate in research — it’s that the conditions of valid consent are harder to guarantee in a custodial environment, so IRBs apply extra scrutiny. This is a direct application of Belmont’s “justice” principle: the burdens of research should not fall disproportionately on populations who are already disadvantaged.

The Belmont Report acknowledges that cognitive or psychiatric impairment may diminish a person’s capacity to give truly informed consent — not eliminate it entirely, but diminish it in ways that require accommodation. The approach is capacity-specific, not diagnosis-specific: a person with schizophrenia may have full capacity to consent to a low-risk study on some days and reduced capacity during an acute episode. A person with early-stage Alzheimer’s may be able to consent to some types of research but not others.

Protections include requiring a legally authorized representative to consent on behalf of someone who lacks capacity, seeking the person’s assent where possible even when they cannot formally consent, and ensuring the research is directly relevant to conditions affecting the population. Your slide should make the point that these protections are grounded in Belmont’s beneficence principle — the obligation to “do no harm” and to maximize benefit. Enrolling a cognitively impaired person in research they cannot understand and would not choose if they could understand is a violation of beneficence, regardless of the study’s scientific value.